Download PDF
Horm Metab Res 1983; 15(10): 471-474
DOI: 10.1055/s-2007-1018762
© Georg Thieme Verlag, Stuttgart · New York

Dissociated Effects of Somatostatin Analogs on Arginine-Induced Insulin, Glucagon and Growth Hormone Release in Acromegalic Patients

B. L. Wajchenberg1 , F. P. Cesar1 , C. E. Leme1 , V. C. Borghi2 , I. T. T. Souza2 , D. G. Neto2 , O. A. Germek2 , D. H. Coy3 , A. M. Comaru-Schally3 , A. V. Schally3
  • 1Diabetes and Adrenal Unit, Hospital das Clinicas, Sao Paulo, Brasil
  • 2Institute of Energy and Nuclear Research, Sao Paulo, Brasil
  • 3V.A. Medical Center and Tulane University School of Medicine, New Orleans, Louisiana, U.S.A.
Further Information

Publication History

1982

1983

Publication Date:
14 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Two analogs of somatostatin (Ala2,D-Trp8,D-Cys14-Somatostatin and L-5F-Trp8-Somatostatin) infused into acromegalics at the rate of 4.5 μg/min suppressed arginine-stimulated growth hormone release more strongly than 6 μg/min somatostatin (110 ± 11% and 129 ± 14%, respectively). Under the same conditions the two somatostatin analogs induced a much smaller inhibition of insulin (33 ± 13% and 44 ± 18%) and glucagon (28 ± 10% and 45 ± 17%, respectively) release than somatostatin did. Somatostatin analogs with dissociated actions could be promising for the treatment of diseases such as acromegaly, diabetes mellitus and some ectopic hormone syndromes.

Key-Words:

Somatostatin Analogs - Treatment of Acromegaly - Diabetes Mellitus